LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
The company focused on developing a novel, reversible, all-endoscopic surgical set of tools, which would serve as a safe and simple alternative to surgical treatment for obesity. Their trans-oral solution would avoid complications and safety issues related to conventional incision-based surgery for obesity. The company's assets were sold in 2013.
BaroSense
Menlo Park, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.